ClinicalTrials.gg
TerminatedNCT04601857Updated Dec 31, 2025Results posted

Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma

A Phase 2 interventional study of Futibatinib and Pembrolizumab in Advanced and Metastatic Urothelial Cancer, sponsored by Taiho Oncology, Inc.. Terminated at 18 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-31.

Sponsored by Taiho Oncology, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor decided to discontinue the study due to strategic considerations and not due to any safety-related concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
43
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of the trial is to evaluate the antitumor activity and confirm the safety for the combination of Fibroblast Growth Factor Receptor (FGFR) inhibitor futibatinib and anti-programmed cell death-1 (PD-1) antibody pembrolizumab in patients with advanced or metastatic urothelial cancer who are not candidates to receive a platinum-based treatment regimens.

02

Conditions studied

  • Advanced and Metastatic Urothelial Cancer

Keywords

  • Futibatinib
  • Pembrolizumab
  • Urothelial cancer
  • FGFR
  • TAS120
  • MK3475 B04
03

In context

Lead sponsor

Taiho Oncology, Inc. is the lead sponsor of 66 studies on the registry; 9 are open to participants now.

Of its 25 completed or terminated interventional studies of FDA-regulated products, 13 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing and able to provide written for the trial.
  2. Age ≥ 18 years of age
  3. confirmed advanced or urothelial carcinoma who have not received systemic treatment for advanced metastatic disease.

    1. Cohort A: must have an FGFR3 mutation or FGFR1-4 fusion/rearrangement.
    2. Cohort B: all other patients with UC (including patients with other FGFR or non-FGFR genetic aberrations and patients with wild-type [non-mutated] tumors)
  4. Unfit for or intolerant to standard platinum-based chemotherapy.
  5. Have an (ECOG) performance status (PS) of 0 to 1.
  6. Adequate organ function.
  7. Have a per 1.1

Exclusion criteria

Exclusion Criteria:

  1. Have received prior therapy with , anti-PD-L1/L2 agent or FGFR inhibitor.
  2. History and/or current evidence of any of the following disorders:

    1. Non-tumor related alteration of the calcium-phosphorus homeostasis that is considered in the opinion of the Investigator.
    2. Ectopic mineralization/calcification considered clinically significant in the opinion of the Investigator.
    3. Retinal or corneal disorder considered clinically significant in the opinion of the Investigator.
  3. Has received a within 30 days prior to the first dose of study drug.
  4. Have an active disease that has required systemic treatment in the past 2 years.
  5. Have a history of (noninfectious) pneumonitis that required or has current pneumonitis.
  6. Have had an allogenic tissue/ organ transplant.
  7. Has known (HIV) and/or history of or C infections, or known to be positive for Hepatitis B antigen (HBsAg)/ Hepatitis B virus (HBV) DNA or Antibody or RNA.
  8. Have known active central nervous system and/or carcinomatous meningitis.
  9. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy.
  10. Has severe (≥Grade 3) to pembrolizumab and/or any of its .
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Cohort A

    Participants with metastatic urothelial carcinoma (UC) and FGFR3 mutation or FGFR1-4 fusion/rearrangement received futibatinib 20 milligrams (mg), orally, once daily (QD), in a 21-day cycle for maximum duration of 590 days along with pembrolizumab 200 mg, intravenously (IV), every 3 weeks (Q3W), in a 21-day cycle for a maximum of 35 doses or a maximum duration of 2 years.

    Drug: Futibatinib · Drug: Pembrolizumab

  • Experimental
    Cohort B

    Participants with metastatic UC (including participants with other FGFR or non-FGFR genetic aberrations and participants with wild type \[non-mutated\] tumors) received futibatinib 20 mg, orally, QD, in a 21-day cycle for maximum duration of 563 days along with pembrolizumab 200 mg, IV, Q3W in a 21-day cycle for a maximum of 35 doses or a maximum duration of 2 years.

    Drug: Futibatinib · Drug: Pembrolizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    ORR was defined as the proportion of participants experiencing a best overall response of partial response (PR) or complete response (CR) according to response evaluation criteria in solid tumors, version 1.1 (RECIST 1.1) criteria based on investigator assessment. Evaluation of target lesions defined a CR as the disappearance of all target lesions and non-target lesions (if applicable), and normalization of tumor marker level; PR was defined as at least a 30 percent (%) decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum of diameters for all target lesion assessments. Evaluation of non-target lesions was defined as the persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits. For both target and non-target evaluations, any pathological lymph node must have had a reduction in short axis to less than (\<)10 millimeters (mm).

    Time frame: Up to 38 months

Secondary outcomes

  1. Disease Control Rate (DCR)

    DCR was defined as the proportion of participants experiencing a best overall response of SD, PR, or CR. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), referencing the smallest sum diameters while on study. Evaluation of target lesions defined a CR as the disappearance of all target lesions and non-target lesions (if applicable), and normalization of tumor marker level; PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum of diameters for all target lesion assessments. Evaluation of non-target lesions was defined as the persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits. For both target and non-target evaluations, any pathological lymph node must have had a reduction in short axis \<10 mm.

    Time frame: Up to 38 months

  2. Duration of Response (DOR)

    DOR was calculated for all responders from the date of first documentation of response (CR or PR) to the first documentation of objective tumor progression or death due to any cause, whichever occurred first. Evaluation of target lesions defined a CR as the disappearance of all target lesions and non-target lesions (if applicable), and normalization of tumor marker level; PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum of diameters for all target lesion assessments. Evaluation of non-target lesions was defined as the persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits. For both target and non-target evaluations, any pathological lymph node must have had a reduction in short axis to \<10 mm.

    Time frame: Up to 38 months

  3. Progression-free Survival (PFS)

    PFS was defined as the time from the first dose of study therapy to the date of death (any cause) or disease progression, whichever occurred first. The PFS was analyzed using a Kaplan-Meier method, with PFS time being censored on the date of the last tumor assessment. The 95% confidence interval (CI) for median PFS was provided using the Kaplan-Meier procedure.

    Time frame: Up to 38 months

  4. Overall Survival (OS)

    OS was defined as the time from the date of the first dose to the death date. Participants without a documented death date were censored on the last date they were known to be alive.

    Time frame: Up to 38 months

  5. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a clinical study participant and does not necessarily have a causal relationship with the study drug. TEAEs are defined as AEs reported up to 30 days after the last dose of any study therapy (safety follow-up) or until the start of new antitumor therapy, whichever is earlier, unless otherwise specified.

    Time frame: Up to 38 months

07

Results

Posted Dec 31, 2025

Participant flow

Participants took part in the study at 18 sites in the United States, France and Spain from 07 January 2021 to 16 September 2025.

Participant flow — Overall Study
MilestoneCohort ACohort B
Started1726
Completed51
Not completed1225
Withdrew: Adverse event/serious adverse event37
Withdrew: Disease progression24
Withdrew: Clinical disease progression21
Withdrew: Radiological progression411
Withdrew: Death10
Withdrew: Reason not specified01
Withdrew: At the participant's request01

Outcome measures

PrimaryObjective Response Rate (ORR)

ORR was defined as the proportion of participants experiencing a best overall response of partial response (PR) or complete response (CR) according to response evaluation criteria in solid tumors, version 1.1 (RECIST 1.1) criteria based on investigator assessment. Evaluation of target lesions defined a CR as the disappearance of all target lesions and non-target lesions (if applicable), and normalization of tumor marker level; PR was defined as at least a 30 percent (%) decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum of diameters for all target lesion assessments. Evaluation of non-target lesions was defined as the persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits. For both target and non-target evaluations, any pathological lymph node must have had a reduction in short axis to less than (\<)10 millimeters (mm).

Time frame:
Up to 38 months
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsCohort ACohort B
Objective Response Rate (ORR)47.1 (23.0 to 72.2)26.9 (11.6 to 47.8)
SecondaryDisease Control Rate (DCR)

DCR was defined as the proportion of participants experiencing a best overall response of SD, PR, or CR. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), referencing the smallest sum diameters while on study. Evaluation of target lesions defined a CR as the disappearance of all target lesions and non-target lesions (if applicable), and normalization of tumor marker level; PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum of diameters for all target lesion assessments. Evaluation of non-target lesions was defined as the persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits. For both target and non-target evaluations, any pathological lymph node must have had a reduction in short axis \<10 mm.

Time frame:
Up to 38 months
Reported as:
Number · percentage of participants
Disease Control Rate (DCR)
percentage of participantsCohort ACohort B
Disease Control Rate (DCR)82.4 (56.6 to 96.2)53.8 (33.4 to 73.4)
SecondaryDuration of Response (DOR)

DOR was calculated for all responders from the date of first documentation of response (CR or PR) to the first documentation of objective tumor progression or death due to any cause, whichever occurred first. Evaluation of target lesions defined a CR as the disappearance of all target lesions and non-target lesions (if applicable), and normalization of tumor marker level; PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum of diameters for all target lesion assessments. Evaluation of non-target lesions was defined as the persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits. For both target and non-target evaluations, any pathological lymph node must have had a reduction in short axis to \<10 mm.

Time frame:
Up to 38 months
Reported as:
Median · months
Duration of Response (DOR)
monthsCohort ACohort B
Duration of Response (DOR)12.32 (6.5 to 24.0)14.46 (3.0 to 23.5)
SecondaryProgression-free Survival (PFS)

PFS was defined as the time from the first dose of study therapy to the date of death (any cause) or disease progression, whichever occurred first. The PFS was analyzed using a Kaplan-Meier method, with PFS time being censored on the date of the last tumor assessment. The 95% confidence interval (CI) for median PFS was provided using the Kaplan-Meier procedure.

Time frame:
Up to 38 months
Reported as:
Median · months
Progression-free Survival (PFS)
monthsCohort ACohort B
Progression-free Survival (PFS)8.3 (3.5 to 18.5)4.1 (2.1 to 8.3)
SecondaryOverall Survival (OS)

OS was defined as the time from the date of the first dose to the death date. Participants without a documented death date were censored on the last date they were known to be alive.

Time frame:
Up to 38 months
Reported as:
Median · months
Overall Survival (OS)
monthsCohort ACohort B
Overall Survival (OS)16.2 (6.6 to NA)18.3 (6.2 to NA)
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

An adverse event (AE) is defined as any untoward medical occurrence in a clinical study participant and does not necessarily have a causal relationship with the study drug. TEAEs are defined as AEs reported up to 30 days after the last dose of any study therapy (safety follow-up) or until the start of new antitumor therapy, whichever is earlier, unless otherwise specified.

Time frame:
Up to 38 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsCohort ACohort B
Number of Participants With Treatment Emergent Adverse Events (TEAEs)1726

Adverse events

Collected over Up to 38 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A7/17 (41.2%)10/17 (58.8%)17/17 (100%)
Cohort B13/26 (50%)12/26 (46.2%)26/26 (100%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventCohort ACohort B
Intestinal obstructionGastrointestinal disorders2/171/26
General physical health deteriorationGeneral disorders2/173/26
PneumoniaInfections and infestations2/171/26
Acute kidney injuryRenal and urinary disorders2/171/26
Urinary tract infectionInfections and infestations1/172/26
ConstipationGastrointestinal disorders1/171/26
HaematocheziaGastrointestinal disorders1/170/26
Multiple organ dysfunction syndromeGeneral disorders1/170/26
ErysipelasInfections and infestations1/170/26
SepsisInfections and infestations1/170/26
Most frequent other events
Showing 10 of 141
Most frequent other events
EventCohort ACohort B
HyperphosphataemiaMetabolism and nutrition disorders12/1713/26
ConstipationGastrointestinal disorders10/179/26
DiarrhoeaGastrointestinal disorders9/1714/26
Dry mouthGastrointestinal disorders9/178/26
Decreased appetiteMetabolism and nutrition disorders9/1713/26
AstheniaGeneral disorders8/179/26
AnaemiaBlood and lymphatic system disorders7/179/26
Blood creatinine increasedInvestigations7/173/26
NauseaGastrointestinal disorders3/179/26
Weight decreasedInvestigations5/179/26

Baseline characteristics

All treated population included all participants in all enrolled population who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Cohort ACohort BTotal
Mean73.1 ± 9.8672.2 ± 10.0372.6 ± 9.86
Sex: Female, Male
Sex: Female, Male(Participants)Cohort ACohort BTotal
Female336
Male142337
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort ACohort BTotal
Hispanic or Latino314
Not Hispanic or Latino71724
Unknown or Not Reported7815
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort ACohort BTotal
Black/African American112
Caucasian/White71522
Other011
Not Reported9918
08

Study locations

18 sites
  • UCSF Helen Diller Family Comprehensive Cancer Center
    San Francisco, California 94158, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Comprehensive Care Centers of Nevada
    Las Vegas, Nevada 89148, United States
  • ICANS - Institut de cancérologie de Strasbourg Europe
    Strasbourg, Bas-Rhin 67200, France
  • Institut Paoli Calmettes - Hôpital de jour
    Marseille, Bouches-du-Rhône 13273, France
  • Centre Georges-François Leclerc
    Dijon, Côte d'Or 21079, France
  • Centre Leon Berard - departement d'oncologie medicale
    Lyon, Rhone 69373, France
  • Centre Regional de Lutte Contre le Cancer de Lorraine
    Vandœuvre-lès-Nancy, 54500, France
  • Institut De Cancerologie Gustave Roussy
    Villejuif, 94805, France
  • ALTHAIA, Xarxa Assistencial Universitària de Manresa
    Manresa, Brcelona 8243, Spain
  • Hospital Clinic de Barcelona
    Barcelona, 08036, Spain
  • Hospital de La Santa Creu i Sant Pau
    Barcelona, 8025, Spain
  • Hospital Universitario Vall d'Hebrón
    Barcelona, 8035, Spain
  • Hospital Universitario Reina Sofia
    Córdoba, 14004, Spain
  • Hospital Universitario HMN Sanchinarro
    Madrid, 28050, Spain
  • Hospital Universitario Marqués de Valdecilla
    Santander, 39008, Spain
  • Hospital la Fe
    Valencia, 46026, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2021 to primary completion in Mar 2024, 38 months.

Results were first posted in Dec 2025, 1 year 9 months after primary completion. A results delay was requested in Mar 2025.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2020
First posted
Oct 26, 2020
StartActual
Jan 7, 2021
Primary completionActual
Mar 8, 2024
CompletionActual
Sep 16, 2025
Results delay requested
Mar 3, 2025
Results first posted
Dec 31, 2025
Last update
Dec 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04601857
Responsible party
Sponsor
First posted
Oct 26, 2020
Start date
Jan 7, 2021
Primary completion
Mar 8, 2024
Completion
Sep 16, 2025
Results posted
Dec 31, 2025
Last update
Dec 31, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Futibatinib

Start the discussion